Introduction One of the most common genetic aberrations associated with breast cancer is
the amplification and overexpression of the ERBB2 proto-oncogene located at chromosome …

Amplification of the ERBB2 oncogene at 17q12 is clinically the most relevant genetic
aberration in breast cancer and several studies have linked ERBB2 activation to poor …

Amplification of the ERBB2 oncogene at 17q12 has been well documented in breast cancer
and has been shown to contribute to a poor clinical outcome. However, systematic surveys …

Aims HER2NEU gene amplification is present in the majority of invasive breast carcinomas
that have HER2 protein overexpression. A subset of breast cancers harbour an increased …

Introduction Segmental duplications (low-copy repeats) are the recently duplicated genomic
segments in the human genome that display nearly identical (> 90%) sequences and …

Purpose Polysomy 17 is frequently found in breast cancer and may complicate the
interpretation of HER-2 testing results. We investigated the impact of polysomy 17 on HER-2 …

Breast carcinomas with amplification of HER2 on chromosome 17 are associated with HER2
protein overexpression, adversely affecting prognosis and predicting response to Herceptin …

Overexpression of the Her‐2/neu (HER2) oncogene is known to confer important prognostic
and predictive value to patients with breast cancer. Controversy exists as to the best method …

BACKGROUND: The current study was performed to determine the impact of polysomy 17
on the interpretation of HER2 testing of invasive breast carcinomas using fluorescent in situ …

Accurate assessment of Her-2/neu (erb-b2) status in breast carcinoma is essential for
therapy planning. Clinical assays are targeted at protein overexpression …